Takeda Pharmaceutical
TAK
347 hedge funds and large institutions have $2.57B invested in Takeda Pharmaceutical in 2019 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 93 increasing their positions, 118 reducing their positions, and 86 closing their positions.
17% more call options, than puts
Call options by funds: $114M | Put options by funds: $97.2M
2.23% less ownership
Funds ownership: 11.43% → 9.2% (-2.2%)
11% less funds holding
Funds holding: 390 → 347 (-43)
21% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 118
30% less capital invested
Capital invested by funds: $3.64B → $2.57B (-$1.08B)
41% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 86
56% less funds holding in top 10
Funds holding in top 10: 16 → 7 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$57.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$24.4M |
| 3 |
D.E. Shaw & Co
New York
|
+$16.1M |
| 4 |
Renaissance Technologies
New York
|
+$14.1M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHCM
Sachem Head Capital Management
New York
|
-$121M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$88.3M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$86M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$44M |
| 5 |
Goldman Sachs
New York
|
-$40.8M |
TAK Hedge Fund Activity: Q2 2019 in Review
347 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2019, worth a combined $2.57B — down 30% from $3.64B a quarter earlier.
Sellers outnumbered buyers: 86 funds closed out of TAK and 51 opened new positions — a net loss of 35 holders — while 118 trimmed existing stakes and 93 added.
The largest buyer was LMR Partners, adding an estimated $57.7M. The largest seller was Sachem Head Capital Management, exiting entirely with an estimated $121M sold.
- 347 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2019, down from 390 in Q1 2019.
- Funds reported $2.57B of Takeda Pharmaceutical stock for Q2 2019, down 30% quarter-over-quarter.
- 51 funds opened new Takeda Pharmaceutical positions in Q2 2019 and 86 closed out, a net change of -35 holders.
- The largest Takeda Pharmaceutical buyer in Q2 2019 was LMR Partners, an estimated $57.7M added.
- The largest Takeda Pharmaceutical seller in Q2 2019 was Sachem Head Capital Management, an estimated $121M sold.
Based on aggregated 13F filings for Q2 2019.